Information Provided By: 
Fly News Breaks for July 25, 2016
VVUS
Jul 25, 2016 | 05:40 EDT
WallachBeth analyst Caroline Palomeque views last week's Markman ruling as a positive development for Vivus. The District Court of New Jersey's ruling to adopt the company's claim constructions on its 10 Qsymia patents may bode well for the overall patent infringement case, Palomeque tells investors in a research note. Qsymia has its last patent expiry in 2029, the analyst points out. She keeps a Buy rating on VIVUS with a $2.80 price target.
News For VVUS From the Last 2 Days
There are no results for your query VVUS
